RGRX : Summary for REGENERX BIOPHARMA COM USD0.001 - Yahoo Finance

U.S. Markets closed

RegeneRx Biopharmaceuticals, Inc. (RGRX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.33+0.01 (+3.16%)
At close: 10:38 AM EST
People also watch:
LCARSNGXAOLSPRTXOXIS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.32
Open0.32
Bid0.00 x
Ask0.00 x
Day's Range0.30 - 0.34
52 Week Range0.25 - 0.75
Volume2,700
Avg. Volume19,995
Market Cap35.41M
Beta-3.12
PE Ratio (TTM)-41.45
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    RegeneRx to Present at 9th Annual LD Micro Investor Conference

    For those who are not available to listen to the live webcast, a replay will be archived on RegeneRx's website at http://regenerx.investorroom.com/events. RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world.

  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
    Capital Cube10 days ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016

    Categories: Yahoo Finance Get free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Novartis AG Sponsored ADR, Sevion Therapeutics, Inc., Akorn, Inc., Johnson & Johnson, Mateon Therapeutics, Inc., Rigel Pharmaceuticals, Inc., Sucampo Pharmaceuticals, ... Read more (Read more...)

  • PR Newswire24 days ago

    RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259

    ROCKVILLE, Md., Nov. 9, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patients have been enrolled in a Phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its sterile, preservative-free eye drop formulation developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. The double-masked, placebo-controlled trial is being sponsored by ReGenTree LLC, a joint venture between RegeneRx and GtreeBNT Co. Ltd. a Korean biopharmaceutical company and is being conducted by Ora Inc., an established contract research organization specializing in the field of ophthalmology.  ARISE-2 is being conducted at multiple sites in the U.S., will enroll approximately 500 dry eye patients, and is expected to be completed and patient data reported in Q4 2017.